Quality of Life of Adult Cancer Survivors Who Have Undergone a Previous Bone Marrow or Peripheral Stem Cell Transplant for a Childhood Hematologic Cancer

Fred Hutchinson Cancer Center750 enrolled

Overview

RATIONALE: Studying quality of life in cancer survivors may help determine the long-term effects of hematologic cancer and may help improve the quality of life for future cancer survivors. PURPOSE: This clinical trial is studying the quality of life of adult cancer survivors who have undergone a previous bone marrow or peripheral stem cell transplant for a childhood hematologic cancer.

OBJECTIVES: * Determine the extent to which adult cancer survivors who have undergone prior bone marrow or peripheral blood stem cell transplantation for a pediatric hematologic malignancy require ongoing health care and whether these needs change with increasing time after transplantation. * Correlate physical capabilities, body image, physical limitations, including sexuality issues which alter or influence lifestyle, with time after transplantation in these patients. * Determine whether cognitive abilities relative to memory and neurobehavioral ratings change with increasing time after transplantation in these patients. * Correlate social and relationship abilities with length of time after transplantation in these patients. OUTLINE: Patients and siblings complete a self-report quality of life questionnaire, including outcome assessments of neuroendocrine function, cognitive abilities, physical capability, and psychosocial behavior. PROJECTED ACCRUAL: Approximately 750 patients (375 adult cancer survivors \[case group\] and 375 siblings \[control group\]) will be accrued for this study within 7 years.

Study Type

OBSERVATIONAL

Enrollment

750

Conditions

Leukemia Lymphoma Myelodysplastic Syndromes

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

DISEASE CHARACTERISTICS: * Case group * Previously treated with an allogeneic, unrelated, syngeneic, or autologous bone marrow or peripheral blood stem cell transplantation for a hematologic malignancy ≥ 5 years ago while enrolled on 1 of the following protocols: * FHCRC-160.06 * FHCRC-179.07T * FHCRC-446.03T * FHCRC-661.04 * FHCRC-697.00 * FHCRC-796.00 * FHCRC-843.00 * Disease-free survivor * Under 18 years of age at time of transplantation * Any prior preparative regimen allowed * Control group * Sex-matched sibling within 5 years of patient's age\* * No chronic illnesses (e.g., cancer, diabetes, or asthma) that require medication * No allergies that limit physical activity NOTE: \*If such a sibling is not available, but another sibling is available, then that sibling would be asked to nominate a friend or relative of the same gender as the patient who is also within 5 years of the patient's age; the patient must consent in order for the control subject to participate PATIENT CHARACTERISTICS: Age * See Disease Characteristics * 18 and over Performance status * Not specified Life expectancy * Not specified Hematopoietic * Not specified Hepatic * Not specified Renal * Not specified Other * Must be able to speak, read, and write English PRIOR CONCURRENT THERAPY: Biologic therapy * See Disease Characteristics Chemotherapy * Not specified Endocrine therapy * Not specified Radiotherapy * Not specified Surgery * Not specified

Outcomes

Primary Outcomes

Neuroendocrine status of disease-free childhood transplant patients at 5 years after transplant and ≥ age 18

Cognitive capability of disease-free childhood transplant patients at 5 years after transplant and ≥ age 18

Physical capability of disease-free childhood transplant patients at 5 years after transplant and ≥ age 18

Psychosocial status of disease-free childhood transplant patients at 5 years after transplant and ≥ age 18